CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering.
In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.
A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.
Researchers report that paternally inherited genes are more likely to be expressed in mice.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.